# Zoetis

> Zoetis develops, manufactures and sells medicines, vaccines and diagnostic tools for pets and livestock. The former Pfizer animal-health business serves veterinarians, livestock producers and pet owners in more than 100 countries, with brands including Apoquel, Simparica Trio, Cytopoint, Librela and Solensia.

- **Founded:** 2012
- **Headquarters:** Parsippany, United States
- **Founders:** Pfizer (Originating parent company; incorporated Zoetis in 2012 and completed separation in 2013)
- **Products:** Apoquel / Apoquel Chewable, Cytopoint, Simparica Trio, Vetscan Imagyst, Solensia
- **Notable:** Independent public company since 2013; NYSE ticker ZTS., Products sold in more than 100 countries., Approximately 300 product lines and 21 manufacturing facilities at year-end 2025.

## Products & services

- **Apoquel / Apoquel Chewable** — Prescription canine dermatology medicines for allergic itch and atopic dermatitis; original tablets launched in the U.S. in 2014.
- **Cytopoint** — Injectable monoclonal antibody for allergic itch and atopic dermatitis in dogs; initial U.S. conditional license in 2015.
- **Simparica Trio** — Monthly prescription canine combination parasiticide for heartworm prevention and specified flea, tick and intestinal parasite indications; U.S. launch in 2020.
- **Vetscan Imagyst** — In-clinic diagnostic platform combining digital imaging, AI analysis for supported sample types and access to expert review.
- **Solensia** — Monthly anti-NGF monoclonal antibody for feline osteoarthritis pain; U.S. FDA approval in 2022.
- **Librela** — Monthly anti-NGF monoclonal antibody for canine osteoarthritis pain; U.S. FDA approval in 2023, with subsequent safety-label updates.
- **Lenivia** — Canine osteoarthritis pain therapy administered every three months; commercial launch in Canada and EU member states announced July 2026.
- **Portela** — Feline osteoarthritis pain therapy administered every three months; commercial launch in Canada and EU member states announced July 2026.
- **Livestock vaccines and therapeutics** — Disease prevention and treatment products for cattle, swine, poultry, sheep and fish; availability and indications vary by market.

## Achievements

- Independent public company since 2013; NYSE ticker ZTS.
- Products sold in more than 100 countries.
- Approximately 300 product lines and 21 manufacturing facilities at year-end 2025.
- Approximately 1,700 R&D colleagues at year-end 2025.
- Commercial launches of Lenivia and Portela in Canada and the EU announced in July 2026.

## Latest updates

- **2026-10** — Announced Iris Knobloch will join the board effective December 1, 2026.
- **2026-09** — Announced Lenivia launch in Great Britain on September 24.
- **2026-08** — Second-quarter revenue was approximately $2.5 billion, flat on a reported basis; revised full-year 2026 revenue guidance to $9.120-$9.320 billion.
- **2026-07** — Announced Lenivia and Portela commercial launches in Canada and EU member states.
- **2025-11** — Disclosed $590 million investment in a Douglasville, Georgia manufacturing site, expected operational in 2029 at the time of announcement.

## Links

- Website: https://www.zoetis.com/
- LinkedIn: https://www.linkedin.com/company/zoetis/
- Twitter/X: https://twitter.com/zoetis
- YouTube: https://www.youtube.com/@ZoetisInc
- Instagram: https://www.instagram.com/ZoetisPetcare
- Facebook: https://www.facebook.com/Zoetis/

---

Profile page: https://yespress.io/zoetis
Published by YesPress — https://yespress.io
Last updated: 2026-10-22